{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:46:29Z","timestamp":1777517189537,"version":"3.51.4"},"reference-count":38,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>Because psoriatic arthritis (PsA) is an inflammatory disease of joints, serum soluble biomarkers specific for chronic joint and bone inflammation may predict future disease severity and response to therapy, thereby informing stratified medicine approaches. The objectives of our systematic review were to determine whether serum soluble bone and cartilage turnover biomarkers are (1) associated with PsA or psoriatic spondyloarthropathy; and (2) associated with disease activity, disease severity, or clinical phenotype. Ten studies met eligibility criteria. Matrix metalloproteinase (MMP)-3, Dickkopf (DKK)-1, macrophage colony-stimulating factor (M-CSF), crosslinked telopeptide of collagen-1, and tumor necrosis factor-related apoptosis-inducing ligand were associated with PsA, with equivocal results for osteoprotegerin (OPG) and bone alkaline phosphatase (ALP). MMP-3, DKK-1, M-CSF, CPII:C2C (ratio of cartilage degradation vs byproduct formation), and possibly OPG were associated with PsA independently of psoriasis. C1-2C (a neoepitope released when type 2 cartilage is degraded by collagenases) was associated with both tender and swollen joint counts, and bone morphogenetic protein-4 with patient global assessment of disease, pain score, and the Bath Ankylosing Spondylitis Disease Activity Index. Bone ALP was associated with disease activity. M-CSF and receptor activator of nuclear factor-\u03baB ligand were associated with several plain radiographic features. No studies have investigated biomarker associations specifically with axial PsA.<\/jats:p>","DOI":"10.3899\/jrheum.140223","type":"journal-article","created":{"date-parts":[[2014,11,2]],"date-time":"2014-11-02T00:36:40Z","timestamp":1414888600000},"page":"21-30","source":"Crossref","is-referenced-by-count":51,"title":["Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy"],"prefix":"10.3899","volume":"42","author":[{"given":"Deepak R.","family":"Jadon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison L.","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Korendowych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"2018112909335038000_42.1.21.1","first-page":"138","article-title":"Bone mineral density in patients with psoriatic arthritis","volume":"28","author":"Frediani","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909335038000_42.1.21.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370802"},{"key":"2018112909335038000_42.1.21.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(03)00056-5"},{"key":"2018112909335038000_42.1.21.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"key":"2018112909335038000_42.1.21.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2018112909335038000_42.1.21.6","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90035-8"},{"key":"2018112909335038000_42.1.21.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2018112909335038000_42.1.21.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120397"},{"key":"2018112909335038000_42.1.21.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201697"},{"key":"2018112909335038000_42.1.21.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq105"},{"key":"2018112909335038000_42.1.21.11","doi-asserted-by":"publisher","DOI":"10.1186\/ar3123"},{"key":"2018112909335038000_42.1.21.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.22843"},{"key":"2018112909335038000_42.1.21.13","unstructured":"Critical appraisal skills programme: making sense of evidence. 11 questions to help you make sense of a case control study. [Internet. Accessed September 30, 2014.] Available from: calder.med.miami.edu\/portals\/ebmfiles\/UM%20CASP%20Case-Controls%20Assessment%20Tool.pdf"},{"key":"2018112909335038000_42.1.21.14","first-page":"635","article-title":"[Bone turnover markers evaluation in psoriatic arthritis]","volume":"112","author":"Ciacli","year":"2008","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"2018112909335038000_42.1.21.15","first-page":"354","article-title":"RANKL\/RANK\/OPG molecular complex\u2014 control factors in bone remodeling in psoriatic arthritis","volume":"115","author":"Ciacli","year":"2011","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"2018112909335038000_42.1.21.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0725-8"},{"key":"2018112909335038000_42.1.21.17","first-page":"1087","article-title":"Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement?","volume":"26","author":"Skoumal","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909335038000_42.1.21.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.11331"},{"key":"2018112909335038000_42.1.21.19","first-page":"443","article-title":"Do adipocytokines play a role in bone turnover in spondyloarthropathies?","volume":"58","author":"Lata","year":"2010","journal-title":"J Invest Med"},{"key":"2018112909335038000_42.1.21.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1528-x"},{"key":"2018112909335038000_42.1.21.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00715.x"},{"key":"2018112909335038000_42.1.21.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012556"},{"key":"2018112909335038000_42.1.21.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090167"},{"key":"2018112909335038000_42.1.21.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2008.06.008"},{"key":"2018112909335038000_42.1.21.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel108"},{"key":"2018112909335038000_42.1.21.26","first-page":"1430","article-title":"Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation","volume":"29","author":"Grisar","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909335038000_42.1.21.27","first-page":"888","article-title":"Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis","volume":"27","author":"Ribbens","year":"2000","journal-title":"J Rheumatol"},{"key":"2018112909335038000_42.1.21.28","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000046"},{"key":"2018112909335038000_42.1.21.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.1.47"},{"key":"2018112909335038000_42.1.21.30","doi-asserted-by":"publisher","DOI":"10.1007\/BF02032102"},{"key":"2018112909335038000_42.1.21.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030809"},{"key":"2018112909335038000_42.1.21.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.22923"},{"key":"2018112909335038000_42.1.21.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.2.161"},{"key":"2018112909335038000_42.1.21.34","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00728-7"},{"key":"2018112909335038000_42.1.21.35","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1400332"},{"key":"2018112909335038000_42.1.21.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120245"},{"key":"2018112909335038000_42.1.21.37","first-page":"198","article-title":"The OMERACT filter for Outcome Measures in Rheumatology","volume":"25","author":"Boers","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909335038000_42.1.21.38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120247"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:47:09Z","timestamp":1543517229000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,1]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.3899\/jrheum.140223"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140223","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,1]]}}}